DK1214340T3 - Muterede antigen-proteiner, der beskytter mod anthrax-toxiner, og som specifikt målretter celler, der indeholder store mængder af celleoverflade-metalproteinaser eller plasminogenaktivator-receptorer - Google Patents

Muterede antigen-proteiner, der beskytter mod anthrax-toxiner, og som specifikt målretter celler, der indeholder store mængder af celleoverflade-metalproteinaser eller plasminogenaktivator-receptorer

Info

Publication number
DK1214340T3
DK1214340T3 DK00989184T DK00989184T DK1214340T3 DK 1214340 T3 DK1214340 T3 DK 1214340T3 DK 00989184 T DK00989184 T DK 00989184T DK 00989184 T DK00989184 T DK 00989184T DK 1214340 T3 DK1214340 T3 DK 1214340T3
Authority
DK
Denmark
Prior art keywords
plasminogen activator
cell surface
target cells
large amounts
cells containing
Prior art date
Application number
DK00989184T
Other languages
English (en)
Inventor
Stephen H Leppla
Shi-Hui Liu
Sarah Netzel-Arnett
Henning Hansen-Birkedal
Thomas Bugge
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK1214340T3 publication Critical patent/DK1214340T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00989184T 1999-09-24 2000-09-22 Muterede antigen-proteiner, der beskytter mod anthrax-toxiner, og som specifikt målretter celler, der indeholder store mængder af celleoverflade-metalproteinaser eller plasminogenaktivator-receptorer DK1214340T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15596199P 1999-09-24 1999-09-24
PCT/US2000/026192 WO2001021656A2 (en) 1999-09-24 2000-09-22 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
EP00989184A EP1214340B1 (en) 1999-09-24 2000-09-22 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors

Publications (1)

Publication Number Publication Date
DK1214340T3 true DK1214340T3 (da) 2005-04-04

Family

ID=22557478

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00989184T DK1214340T3 (da) 1999-09-24 2000-09-22 Muterede antigen-proteiner, der beskytter mod anthrax-toxiner, og som specifikt målretter celler, der indeholder store mængder af celleoverflade-metalproteinaser eller plasminogenaktivator-receptorer

Country Status (10)

Country Link
US (3) US7468352B1 (da)
EP (1) EP1214340B1 (da)
AT (1) ATE283280T1 (da)
AU (1) AU771632B2 (da)
CA (2) CA2793128A1 (da)
DE (1) DE60016256T2 (da)
DK (1) DK1214340T3 (da)
ES (1) ES2233495T3 (da)
PT (1) PT1214340E (da)
WO (1) WO2001021656A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763451B2 (en) 2001-11-09 2010-07-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing Bacillus anthracis protective antigen for use in vaccines
US7201912B2 (en) * 2002-04-12 2007-04-10 Emergent Biodefense Operation Lansing Inc. Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
WO2004070001A2 (en) * 2002-11-15 2004-08-19 Gen-Probe Incorporated Assay and compositions for detection of bacillus anthracis nucleic acid
US20080166375A1 (en) * 2003-05-06 2008-07-10 The Government Of The United States Of America, As Rep. By The Secretary Of Health And Human Service Activation of Recombinant Diphtheria Toxin Fusion Proteins by Specific Proteases Highly Expressed on the Surface of Tumor Cells
US7947289B2 (en) 2004-02-09 2011-05-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
WO2008076939A2 (en) * 2006-12-14 2008-06-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculature
CN101881760B (zh) * 2009-09-30 2013-01-02 中国人民解放军防化指挥工程学院 有毒化学品的毒害效果度量方法
US9079952B2 (en) 2011-01-10 2015-07-14 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
US9555064B2 (en) 2011-08-02 2017-01-31 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY DEPT. OF HEALTH AND HUMAN SERVICES Protease-deficient Bacillus anthracis
CA2865243A1 (en) * 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
EP2887966B1 (en) 2012-08-22 2018-07-18 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Engineered anthrax lethal toxin for targeted delivery
US10568929B2 (en) 2015-08-19 2020-02-25 University Of Maryland, Baltimore Engineered anthrax protective antigen proteins for cancer therapy
CA2996767A1 (en) 2015-08-27 2017-03-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified anthrax toxin protective antigen
WO2017035508A1 (en) 2015-08-27 2017-03-02 Collier R John Compositions and methods for treatment of pain
CN112654633A (zh) 2018-06-22 2021-04-13 科优基因公司 基于细胞因子的可生物活化药物及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
WO1994025616A1 (en) * 1993-04-28 1994-11-10 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
US7947289B2 (en) * 2004-02-09 2011-05-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics

Also Published As

Publication number Publication date
EP1214340A2 (en) 2002-06-19
DE60016256T2 (de) 2005-12-15
WO2001021656A2 (en) 2001-03-29
CA2385122A1 (en) 2001-03-29
AU2572501A (en) 2001-04-24
DE60016256D1 (de) 2004-12-30
US20090142794A1 (en) 2009-06-04
PT1214340E (pt) 2005-04-29
WO2001021656A3 (en) 2002-01-17
US8791074B2 (en) 2014-07-29
US7468352B1 (en) 2008-12-23
US20140378654A1 (en) 2014-12-25
CA2385122C (en) 2012-12-18
ES2233495T3 (es) 2005-06-16
EP1214340B1 (en) 2004-11-24
AU771632B2 (en) 2004-04-01
CA2793128A1 (en) 2001-03-29
ATE283280T1 (de) 2004-12-15
US9403872B2 (en) 2016-08-02

Similar Documents

Publication Publication Date Title
DK1214340T3 (da) Muterede antigen-proteiner, der beskytter mod anthrax-toxiner, og som specifikt målretter celler, der indeholder store mængder af celleoverflade-metalproteinaser eller plasminogenaktivator-receptorer
Salvesen et al. Covalent binding of proteinases in their reaction with α2-macroglobulin
Meyer et al. Theta, a new class of glutathione transferases purified from rat and man
Sottrup-Jensen et al. Amino-acid sequence of activation cleavage site in plasminogen: homology with" pro" part of prothrombin.
AR021139A1 (es) Acidos nucleicos y polipeptidos de activadores de la transcripcion y metodos de uso de los mismos
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
TR200000547T2 (tr) Lignin biyosentezi için enzimleri kodlayan genler ve bunların kullanımı.
MXPA03002218A (es) Peptidos antimicrobianos y metodos de uso.
NO995475D0 (no) Kjemiske forbindelser
BR0014516A (pt) Composições e métodos de uso de delta-endotoxina do bacilo thuringiensis ativo de lepidopteran
DE69535352D1 (de) Expression der bazillus thuringiensis cry-proteine in pflanzen-plastiden
DK0544777T3 (da) Enzymatisk detergentsammensætning og fremgangsmåde til enzymstabilisering
ATE350470T1 (de) Durch thrombin spaltbare chimäre proteine
Nakagawa et al. Dissociation of m-calpain subunits occurs after autolysis of the N-terminus of the catalytic subunit, and is not required for activation
Tschesche et al. Tissue kallikrein effectively activates latent matrix degrading metalloenzymes
DK1222298T3 (da) Vektorer og fremgangsmåder til rekombinant proteinekspression
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
DE69906509D1 (de) Herstellung einzelner genprodukte eines chimären fusionsproteins durch spaltung mit überall vorkommenden endoproteasen
DK0458937T3 (da) Varianter af PAI-2
Stan-Lotter et al. Isolation of a chymotrypsinogen B-like enzyme from the archaeon Natronomonas pharaonis and other halobacteria
Basak et al. A rapid fluorometric assay for the proteolytic activity of SKI‐1/S1P based on the surface glycoprotein of the hemorrhagic fever Lassa virus
MX9702776A (es) Proteinas de proteasa de pulgas, moleculas de acido nucleico, y usos de las mismas.
ATE491785T1 (de) Oxidoreduktase
WO2004099254A3 (en) Activation of recombinant diphtheria toxin fusion proteins by specific proteases highly expressed on the surface of tumor cells
MXPA03008438A (es) Toxina insecticida de bacillus thuringiensis modificada sensible a pepsina.